



The Commonwealth of Massachusetts
 Executive Office of Health and Human Services
 One Ashburton Place, Room 1109
 Boston, Massachusetts 02108

CHARLES D. BAKER
 Governor

KARYN E. POLITO
 Lieutenant Governor

MARYLOU SUDDERS
 Secretary

Tel: (617) 573-1600
 Fax: (617) 573-1891
www.mass.gov/eohhs

Administrative Bulletin 21-07

101 CMR 320.00: *Clinical Laboratory Services*

Effective January 1, 2021

- (1) CPT 2021 Coding Updates; and
- (2) CPT 2020 Coding Updates

Part I: 2021 CPT Coding Updates

Pursuant to 101 CMR 320.01(4), the Executive Office of Health and Human Services is adding new procedure codes and deleting outdated codes, effective for dates of service on and after January 1, 2021. As set forth in 101 CMR 320.01(4)(c), the rates for newly added codes are calculated according to the rate methodology used in setting clinical laboratory rates. Added codes without Medicare fees are reimbursed at individual consideration (I.C.). Rates listed in this administrative bulletin are applicable until revised rates are issued by the EOHHS. Deleted codes are not available for use for dates of service after December 31, 2020.

Code	Change	Rate	Code Description
80143	Addition	\$13.77	Measurement of acetaminophen
80151	Addition	\$13.77	Measurement of amiodarone
80161	Addition	\$13.77	Measurement of carbamazepine-10,11-epoxide
80167	Addition	\$13.77	Measurement of felbamate
80179	Addition	\$13.77	Measurement of salicylate
80181	Addition	\$13.77	Measurement of flecainide
80189	Addition	\$20.03	Measurement of itraconazole
80193	Addition	\$28.50	Measurement of leflunomide
80204	Addition	\$28.50	Measurement of methotrexate
80210	Addition	\$20.03	Measurement of rufinamide
81168	Addition	\$153.18	Gene analysis (CCND1/IGH (t(11;14))) translocation analysis
81191	Addition	\$153.18	Gene analysis (neurotrophic receptor tyrosine kinase 1) translocation analysis



Code	Change	Rate	Code Description
81192	Addition	\$153.18	Gene analysis (neurotrophic receptor tyrosine kinase 2) translocation analysis
81193	Addition	\$153.18	Gene analysis (neurotrophic receptor tyrosine kinase 3) translocation analysis
81194	Addition	\$382.96	Gene analysis (neurotrophic receptor tyrosine kinase 1, 2, and 3) translocation analysis
81278	Addition	\$153.18	Gene analysis (IGH@/BCL2 (t(14;18)) translocation analysis
81279	Addition	\$136.84	Gene analysis (Janus kinase 2) targeted sequence analysis
81338	Addition	\$111.08	Gene analysis (MPL proto-oncogene, thrombopoietin receptor) for detection of common variants
81339	Addition	\$136.84	Gene analysis (MPL proto-oncogene, thrombopoietin receptor) sequence analysis of exon 10
81347	Addition	\$142.79	Gene analysis (splicing factor [3b] subunit B1) for detection of common variants
81348	Addition	\$129.60	Gene analysis (serine and arginine-rich splicing factor 2) for detection of common variants
81351	Addition	\$474.26	Gene analysis (tumor protein 53) full sequence analysis
81352	Addition	\$243.47	Gene analysis (tumor protein 53) targeted sequence analysis
81353	Addition	\$227.58	Gene analysis (tumor protein 53) targeted sequence analysis for detection of known familial variant
81357	Addition	\$142.79	Gene analysis (U2 small nuclear RNA auxiliary factor 1) for detection of common variants
81360	Addition	\$142.79	Gene analysis (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) for detection of common variants
81419	Addition	\$1,809.24	Gene analysis panel for evaluation of genes associated with epilepsy
81513	Addition	\$105.39	Measurement of RNA of bacteria in vaginal fluid specimen
81514	Addition	\$194.32	Measurement of DNA of bacteria in vaginal fluid specimen
81529	Addition	\$5,314.91	mRNA gene analysis of 13 genes in skin melanoma tissue specimen
81546	Addition	\$2,660.04	mRNA gene analysis of 10,196 genes in fine needle aspiration thyroid specimen, reported as category result (e.g. benign, suspicious)
81554	Addition	\$4,063.95	mRNA gene analysis of 190 genes associated with lung disease (idiopathic pulmonary fibrosis) in transbronchial biopsy specimen of lung
82077	Addition	\$12.76	Measurement of alcohol level in specimen other than breath or urine
82681	Addition	\$20.64	Direct measurement of free estradiol (hormone)

Code	Change	Rate	Code Description
87636	Addition	I.C.	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique
87637	Addition	I.C.	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique
87811	Addition	I.C.	Infectious agent antigen detection by immunoassay with direct optical (<i>i.e.</i> , visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])
81545	Deletion	\$2,659.89	Oncology (thyroid), gene expression analysis of 142 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (<i>e.g.</i> , benign or suspicious)
87450	Deletion	\$8.75	Infectious agent antigen detection by immunoassay technique, (<i>e.g.</i> , enzyme immunoassay [EIA], enzymelinked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; single step method, not otherwise specified, each organism

Part II: 2020 CPT Coding Updates

Pursuant to 101 CMR 320.01(4), the Executive Office of Health and Human Services is adding a new procedure code, effective for dates of service on and after November 10, 2020. As set forth in 101 CMR 320.01(4)(c), the rates for newly added codes are calculated according to the rate methodology used in setting clinical laboratory rates. Added codes without Medicare fees are reimbursed at individual consideration (I.C.). Rates listed in this administrative bulletin are applicable until revised rates are issued by the EOHHS.

Code	Change	Rate	Code Description
87428	Addition	I.C.	Infectious agent antigen detection by immunoassay technique, (<i>e.g.</i> , enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (<i>e.g.</i> , SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B